title: LONG-TERM OUTCOMES IN PATIENTS WITH VITREOMACULAR TRACTION TREATED WITH A SINGLE INTRAVITREAL INJECTION OF OCRIPLASMIN.
abstract: OBJECTIVE
  To report long-term outcomes in patients with vitreomacular traction injected with intravitreal ocriplasmin.
  
  
  METHODS
  Interventional case series.
  
  
  METHODS
  A 64-year-old woman and a 46-year-old woman.
  
  
  RESULTS
  In Case 1, a 64-year-old woman with focal vitreomacular traction with impending macular hole presented with a visual acuity of 20/80 +1 and was injected with ocriplasmin 11 days later. Visual acuity continued to improve and stabilized through 60 weeks of follow-up with a final visual acuity of 20/50. Vitreomacular traction release was confirmed by optical coherence tomography 6 weeks after injection.In Case 2, a 46-year-old woman with focal vitreomacular traction presented with a visual acuity of 20/60 and received ocriplasmin treatment the same day. Vitreomacular traction release was confirmed by optical coherence tomography 2 days later. After subsequent worsening of visual acuity, pneumatic retinopexy and pars plana vitrectomy were performed. Visual acuity continued to improve and stabilize throughout the 52-week follow-up with a final visual acuity of 20/25.
  
  
  CONCLUSIONS
  We present here two patients with focal vitreomacular traction treated with ocriplasmin and followed up long-term for up to one year. In both cases, visual acuity improved compared with baseline and stabilized after ocriplasmin treatment. These cases add to the growing literature demonstrating resolution of symptoms after ocriplasmin treatment over longer follow-up periods.
authors: Medical Center Ophthalmology Associates, San Antonio, Texas.
authors: Lyndon
authors: L
authors: Tyler
authors: Michael
authors: M
authors: Singer
authors: Darren
authors: D
authors: Bell
mesh_terms: D005260:Female; D005341:Fibrinolysin / Q000008:administration & dosage*; D006801:Humans; D058449:Intravitreal Injections; D008875:Middle Aged; D010446:Peptide Fragments / Q000008:administration & dosage*; D012164:Retinal Diseases / Q000188:drug therapy*; D000267:Tissue Adhesions / Q000188:drug therapy; D016896:Treatment Outcome; D020255:Vitreous Detachment / Q000188:drug therapy*
chemical_list: D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin